Skip to main content

Diabetes

  • Harris Teeter launches donation card campaign to support JDRF

    MATTHEWS, N.C. — Harris Teeter on Thursday launched a donation card campaign to support JDRF, a charitable funder of research toward curing, treating and preventing Type 1 diabetes and its complications.

  • Community-based diabetes efforts should involve retail pharmacies

    The YMCA is offering a demonstration project to show that its YMCA Diabetes Prevention Program — part of the Centers for Disease Control and Prevention's broader National Diabetes Prevention Program — can lower the incidence of Type 2 diabetes and reduce medical costs incurred by Medicare.

  • FDA approves Aurobindo diabetes drug

    HYDERABAD, India — The Food and Drug Administration has approved a generic diabetes drug made by Aurobindo Pharma, the drug maker said.

    Aurobindo announced the approval of pioglitazone tablets in the 15 mg, 30 mg and 45 mg strengths, in addition to the earlier tentative approval it received for pioglitazone and metformin hydrochloride tablets in the 15 mg/500 mg and 15 mg/850 mg strengths.

  • Study finds dramatic improvement in blood-sugar control among diabetes patients

    NEW YORK — Control of A1C, blood pressure and cholesterol among patients with diabetes has improved markedly, but more room for improvement remains, according to a new study.

  • Reports: Insurers, employers support YMCA diabetes program

    NEW YORK — The YMCA is sponsoring a diabetes-control program that some say could slow the disease's spread, according to published reports.

  • Mylan, Biocon enter deal on generic analog insulins

    PITTSBURGH — Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

    Under the deal, Mylan will have the rights to develop and market Biocon's Glargine, Lispro and Aspart, respectively generic versions of Sanofi's Lantus, Eli Lilly's Humalog and Novo Nordisk's NovoLog.

  • FDA turns down two Novo Nordisk insulin products

    BAGSVÆRD, Denmark — The Food and Drug Administration declined to approve two insulin products made by Danish drug maker Novo Nordisk, the company said Sunday.

    Novo Nordisk said it received complete response letters from the FDA for Tresiba (insulin degludec) and Ryzodeg (insulin degludec and insulin aspart). The FDA issues a complete response letter when it has finished reviewing an application for a drug, but determines that the application can't be approved in its current form.

  • Type 1 diabetes spikes among Philadelphia children, study finds

    PHILADELPHIA — While much of the attention to diabetes has focused on the dramatic rise of Type 2 diabetes among adults and children alike, a new study by a researcher in Philadelphia has found a spike in Type 1 diabetes among children as well.

X
This ad will auto-close in 10 seconds